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The clinical application of antisense oligonucleotides (ASOs) is becoming more of a reality as several drugs have 
been approved for the treatment of human disorders and many others are in various phases in development and 
clinical trials. ASOs are short DNA/RNA oligos which are heavily modified to increase their stability in 
biological fluids and retain the properties of creating RNA-RNA and DNA-RNA duplexes that knock-down or 
correct genetic expression. This review outlines several strategies that ASOs utilize for the treatment of various 
congenital diseases and syndromes that develop with aging. In addition, we discuss some of the mechanisms for 
specific non-targeted ASO internalization within cells.   
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Introduction 
One of the growing fields of interest pertaining to nucleic 
acid-based gene silencing/modification is the application of 
antisense oligonucleotides (ASOs). ASOs are chemically 
modified nucleic acid sequences that serve as highly 
selective sequence pairs to specific regions of mRNA and 
regulate the translation of genetic material into functional 
proteins. ASOs bind complementary RNA by Watson-Crick 
base pairing and can suppress gene expression via a number 
of distinct antisense mechanisms. ASOs which contain 
stretches of >5 DNA nucleotides activate the RNase H 
antisense mechanism. RNaseH1 is a ubiquitously expressed 
endonuclease which selectively cleaves the RNA strand of a 
DNA/RNA heteroduplex [1]. ASOs of other chemical 
compositions can bind RNA to modulate splicing, arrest 
translation or sequester endogenous microRNAs [2] (Fig. 1).  
The phosphodiester (PO) backbone of DNA and RNA is 
susceptible to nuclease mediated degradation which limits 
application of unmodified oligonucleotides as therapeutics. 
In contrast, chemical modifications of the backbone enhance 
the metabolic stability of oligonucleotides which enables 
their use for therapeutic applications. One of the most widely 
used modifications in oligonucleotide therapeutics is the 
phosphorothioate modification [3]. The phosphorothioate (PS) 
modification replaces a non-bridging oxygen atoms in the PO 
linkage with a sulfur atom. This increases ASO stability in 
biological fluids and also enhances their protein binding and 
cell uptake properties [4]. ASO stability is essential for the 
molecules to not only remain intact while in circulation, but 
also to be biologically active and internalized into the cell for 
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gene silencing. However, this mechanism may only work if 
the ASO successfully navigates past the cell 
plasma/endosomal membranes to target the specific mRNA 
of interest. The mechanism for ASO internalization is not 
well understood, though it is thought that efficient uptake 
involves specific protein receptors [5, 6]. At the present time, it 
is believed that clathrin-mediated endocytic receptor(s) 
allows ASO internalization at concentrations in the nM-µM 
range [6-8].  
Recent works focused on increasing the understanding of 
these drugs have enabled great strides in the therapeutic 
application. The FDA approved ASO therapeutic uses such 
as treatment for familial hypocholesteremia, with many 
others in phase III clinical trials [9-11]. New designs are 
constantly being developed to increase effectiveness of these 
drugs, as well as new approaches to different diseases, while 
at the same time decreasing potential off-target side-effects [6, 
12]. The focus of this review is to highlight the development 
of ASOs in clinical drug development for a variety of 
diseases, as well as examine recent research to answer 
fundamental questions of cellular ASO internalization and 
systemic clearance.  
Backbone Modifications for single stranded ASOs 
One key aspect of ASO stability and functionality is 
derived from the modifications on the phosphate backbone of 
the nucleotide sequence. Second generation ASOs are 
comprised of a central gap region of PS DNA flanked on 
either ends with 2’-methoxyethyl RNA (MOE) nucleotides. 
The MOE nucleotides enhance binding affinity for 
complementary RNA and further enhance metabolic stability 
which results in longer effectiveness in the clinic [3, 13]. Other 
ASO backbone structures such as phosphodiester (PO) or 
methylphosphonates (MP) have been explored [14], but the PS 
backbone modifications to have high stability both in-vitro 
and in-vivo systems [6], in addition to in-vivo internalization 
[15] for single stranded ASOs. 
MP oligonucleotides, which have reduced charge, have 
higher nuclease stability than PS-ASOs [16]. However, the 
lack of charge on the MP molecule reduces protein binding 
and cellular uptake [17-19]. Novel techniques are being utilized 
to increase the activity of ASOs, with a majority of clinical 
drugs having a PS-2’-methoxyethyl (2’-MOE) modification 
of the ribose sugar which increases the Tm of RNA by 2o C 
for each modification, while also aiding to reduce access to 
Figure 1. RNase H mediated destruction of targeted mRNA. ASOs are internalized in the cells by several mechanisms 
(clathrin/caveolin-mediated endocytosis, micropinocytosis, etc.) in which a small subset of the ASOs escape into the cytoplasm and/or 
nucleus. Hybridization of the ASO with complementary hnRNA or mRNA induces RNase H cleavage of the RNA while leaving the ASO 
intact for subsequent hybridizations.   
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the linkage of the backbone [2] (Fig. 2). It is important to note 
that while PS-ASOs are currently being utilized based on 
their increased activity, the PS modifications are relatively 
easy to synthesize compared to other phosphate 
modifications [19]. Currently, over 35 ASOs are in clinical 
development, and of these, at least a majority contain PS 
backbone structures, and many newer chemical structures 
contain 2’-MOE modifications as well [2].  
Diseases Targeted by ASOs 
Duchenne’s muscular dystrophy 
Duchenne’s muscular dystrophy (DMD) is a rare but 
debilitating X-linked disease causing muscle wasting by 
mutations arising from the DMD gene, which codes for 
dystrophin. This protein has been determined to connect the 
sub-sarcolemmal cytoskeleton to the extra-cellular matrix 
(ECM). Dystrophin, along with the dystrophin associated 
glycoprotein complex (DGC) work to stabilize muscle fibers 
during muscle contraction from the binding of the 
cytoskeleton to the ECM. When this protein is lost due to the 
DMD gene mutations, it leads to muscle degeneration, 
inflammation, and overall progression of DMD [20]. This 
disease is the most common fatal neuromuscular disorder 
found in children, which affects 1 in 3,500 males [20]. Patients 
are traditionally treated by the age of 5 to prevent premature 
death when diagnosed at an early age. Although if left 
untreated (without preventative measures), children often 
suffer from cardiac or respiratory failure leading to death 
before the age of twenty [20-22]. The disease is caused by 
genetic missense or nonsense mutations in the open reading 
frame of the DMD gene, dystrophin [22].  
Antisense oligonucleotides may utilize multiple splicing 
mechanisms for when a gene is mistranslated including exon 
skipping, cryptic splicing restoration, or even changing levels 
of alternate gene splicing [23]. One of the early ASOs used in 
DMD treatment, PRO-051, or Drisapersen, utilized exon 
splicing modulation for exon 51 (of the 79 exons present) of 
Dystrophin to force skip this exon, allowing for rescue of the 
ORF [24]. Although it proceeded into stage III of clinical 
trials, it failed to be awarded FDA approval due to the high 
doses required for effective treatment and long-term toxicity 
side-effects [25]. Drisapersen was a modified 2’O-Me RNA 
modification. A second drug was developed with a 
morpholino backbone [2], which utilizes excision of the 
pre-mRNA splicing of dystrophin’s exon 51 [26] based on the 
same rescue of the ORF as Drisapersen. The mechanism of a 
morpholino modified ASO allows for hybridization binding 
to exon 51, which when bound does not allow the splicing 
machinery to recognize it, allowing for the ORF to remain 
intact, while removing the mutated region [23] (Fig. 3A). 
Currently, this drug is in stage III clinical trials and has 
demonstrated lower toxicity than its 2’ O-Me counterpart. 
Although further testing is required before FDA approval, 
there seems to be hope that this morpholino-based ASO will 
help in future treatments of DMD, based on the 
improvements from the previous 2’ O-Me drug. 
Spinal Muscular Atrophy 
Spinal muscular atrophy (SMA), not to be confused with 
spinal muscular dystrophy, is currently the leading cause of 
genetic infant mortality. This disease causes motor neurons 
in the central nervous system to decay and lose function [27]. 
Loss of neuromuscular junctions causes muscles to weaken 
and atrophy over time. The loss of muscle function can have 
devastating secondary impacts from sleeplessness to 
scoliosis, joint contractures, and respiratory failure. This 
genetic disorder arises from mutations on exon 7 of the 
SMN1 gene, which codes for the survival motor neuron 
proteins, with 95-98% of patients displaying a homozygous 
trait of this gene [27]. SMN proteins localize to the cytosol 
Figure 2. Backbone structures of ASO modifications. A. Unmodified phosphodiester 
backbone. B. Generation 1 phosphorothioate (PS-ASO) modification. C. Generation 2 
2’-methoxyethyl phosphorothioate (2’ MOE-PS-ASO) modification.  
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and nucleus, where they are involved in a multiprotein 
complex. These proteins are involved in RNP complex 
formation, and have been shown to accumulate in Cajal 
bodies [28, 29]. SMN2 is also involved in this disease, 
however, the copy number increases in the presence of 
SMN1 mutations, leading to phenotype modifications.  
Currently, there is no specific treatment for the disease 
Figure 3. Exon skipping as a mechanism for “gene” correction. A. The ASO mechanism for the treatment of Duchenne’s Muscular 
Dystrophy (DMD) in which the ASO binds to exon 51 containing the mutation and force skips the exon in transcription producing a slightly 
shorter but active gene product. B. In cases of Spinal Muscular Atrophy (SMA), heterogenous nuclear ribonuclear proteins (hnRNPs) bind 
to exon 7 and prevent further hnRNA modification and subsequent translation. C. SMA treatment with a 2’-methoxyethyl (2’-MOE) modified 
ASO (ASO-10-27) displaces hnRNPs and allows translation of the full-length gene product. D. SMA treatment with a 2’-Fluoro (2’-F) 
modified ASO recruits Interleukin Enhancer 2 and 3 proteins which displace hnRNPs and allow for the translation of a shorter mRNA 
producing a smaller protein product that is still partially active. Figure adapted and modified from Aartsma-Rus et al. [23] and Rigo et al. 
[35] 
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itself, as most therapies are for treating the symptoms [30]. 
One potential therapy, proposed a decade ago, was to utilize 
quinizoline derivatives as a potential mechanism for 
increasing SMN2 promoter activity to induce SMN splicing 
patterns to relieve the mutated gene [31]. A study, compiling 
multiple compounds that increased SMN promotor activity 
identified these derivatives as a potential target with a 2.5 
fold increase in activity [32]. Although this mechanism did 
produce improvement of motor function in mouse models, a 
work-stop was issued and the drug company has canceled 
clinical phase II testing [33, 34].  
Modulating splicing of mRNA can also be accomplishes 
using ASOs. This class utilizes pre-messenger RNA as a 
source for correcting an aberrant mRNA product. When 
untreated with ASOs heterogenous nuclear 
ribonuclearproteins (hnRNPs) are recruited to the exon to 
silence the targeted region [35]. One example for treatment to 
inhibit hnRNP activation of pre-mRNA in SMA is 
ASO-10-27, which works to provide corrected SMN 
expression via a gene splicing mechanism similar to that of 
the DMD example [23, 36] (Fig. 3B-D). ASO-10-27 is a 
generation 2 drug that is used to boost functional SMN 
production by careful splice modification of SMN2, based on 
its paralogous gene similarity to SMN1 [33, 36]. The key 
mechanism for this ASO is when bound, it does not allow for 
hnRNP to bind to the targeted exon 7 by blocking the 
binding site, allowing for the gene to remain intact. 
Interestingly, a 2’-fluoro modified ASO, recruits interleukin 
enhancer-binding 2 and 3 complex (ILF2/3) to bind to the 
active site causing the exon to be skipped [35]. Currently, the 
ASO-10-27 MOE modified drug demonstrates marked 
improvement in clinical trials from the mechanism of exon 7 
splicing, as this therapy is currently in clinical phase III 
trials. However, it is worth nothing that other chemical 
modifications are being studied for future use as a new 
mechanism for treatment of SMA along with a wide variety 
of other potential disease targets. 
Factor XI for Thrombosis 
Thrombosis (blood clotting) is a major health issue that 
may arise from adverse drug reactions, post-surgical 
outcomes, stroke, myocardial infarction, or spontaneously by 
ill-defined mechanisms. Factor XI is a serine protease 
enzyme that is converted to Factor XIa and directly involved 
in the coagulation cascade [37]. This enzyme has been 
targeted as a potential upstream inhibitor for thrombosis by 
ASO-based gene knock-down therapy utilizing a second 
generation ASO (FXI-ASO), which has a 2’-O-MOE RNA 
modification coinciding with the PS modification allowing 
for this ASO to stably be incorporated into the cell for 
targeting factor XI mRNA [37]. The rationale for targeting this 
specific factor, was the lack of potential bleeding events, 
while also lowering the rate of blood clotting. FXI-ASO was 
tested in animals and showed no disruption of homeostasis 
during knock-down of Factor XI protein activity by over 
90% [38]. FXI-ASO is able to bind to mRNA of factor XI in 
the liver, specifically in the hepatocytes which is the primary 
site of factor XI formation [39]. The hepatic inhibition leads to 
a downstream reduction of plasma factor XI levels. 
Currently, this drug is in phase II of clinical trials, as it has 
been subject to a human open-label phase study, by which no 
treatment disguise or placebo is used [40]. This study showed 
that at higher doses, there were no reported toxicity events, 
and all noted side-effects were negligible, as the patients 
responded to positive anti-coagulation without increased 
bleeding risk, [40] which is novel to most anti-coagulant based 
treatments. At this time, more work needs to be done since 
ASO targeting of hepatic factor XI production has shown 
promising results for the future treatment of patients with 
high risk of suffering from thrombosis. 
Hyperlipoproteinemia/Apolipoproteinemia 
Hyperlipoproteinemia, also known as 
hypercholesterolemia, is a condition in which increased 
amounts of serum low density lipoprotein (LDL) cholesterol 
accumulates in the blood stream. This is traditionally a 
precursor for cardiovascular diseases, as well as plaque 
formation based on the age at which onset occurs [41]. There 
are a variety of factors that contribute to a patient diagnosed 
with this disease, though there is a genetic predisposition, 
known as familial hypercholesterolemia (FH). FH is thought 
to be most commonly associated with a mutation in the LDL 
receptor (LDLR) gene in patients expressing either 
heterozygous, with one allele being mutated, or homozygous 
genes, with both alleles mutated [42].  Although the LDLR 
mutation is very common in FH diagnoses, there are also 
reported cases indicating that a mutation in apolipoprotein B 
(ApoB) can also cause FH, with phenotypic similarities that 
make diagnosis virtually indistinguishable from other causes. 
FH caused by dysfunctional ApoB is found in approximately 
1 in 500 people in Western cultures [43]. A common form of 
treatment for FH is to prescribe statins, which effectively 
reduce cholesterol synthesis by HMG-CoA reductase, 
although most patients require additional drug therapy and 
lifestyle changes [42].  
With the advances in ASO technology, a RNase H1 active 
second generation 2’-O-MOE PS-ASO (Mipomersen) was 
developed that complements the coding region of ApoB 
mRNA located at position 3249-3268 of the mRNA [44]. 
Following subcutaneous injection, Mipomersen is distributed 
across a wide variety of tissues including the liver, and it has 
been determined through clinical studies that it effectively 
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reduces plasma LDL cholesterol levels. Additionally, it has 
been shown that Mipomersen does not have deleterious 
effects on high density lipoproteins (HDL), which are 
important for lipid transport to liver and other steroidogenic 
organs [44]. Due to the success of Mipomersen by both low 
toxicity reports and high apolipoprotein B inhibition, it has 
been approved by the FDA for clinical use for FH treatment 
[9]. Currently, with more mutations being discovered that lead 
to LDL Cholesterol accumulation, additional ASO-based 
drugs are currently being developed in the clinical pipeline. 
A few of these are: Ionis-APO(a)Rx which is a second 
generation (2’-O-MOE) drug that is currently in clinical trials 
for treatment of the protein apolipoprotein A, which is 
implicated in cardiovascular disease and aortic valve stenosis 
[45] and Apolipoprotein C-III and its role in plasma 
triglyceride levels. Currently, improvements and testing for 
2’-O-MOE ASO Ionis 304801 (Apo-C3Rx) is in refinement to 
reduce plasma triglyceride levels by binding to the the 
ApoC3 mRNA to reduce apolipoprotein C-III production [10]. 
This drug is currently in clinical phase III trials.  
Cellular uptake of Phosphorothioate Modified ASOs 
The understanding of uptake and clearance of PS-ASOs is 
essential to calibrate the dose and pharmacology of 
therapeutic ASOs. Cellular endocytosis of ASOs is of high 
interest as a high number of targeted proteins are synthesized 
by the liver [5, 10, 24]. PS-ASOs, as mentioned previously have 
a higher stability based on the chemical modifications, 
allowing them to remain intact for cellular uptake. The 
rationale for understanding the pharmacokinetics of ASOs is 
to correlate effective dose with clearance rates to optimize 
effectiveness while reducing potentially harmful side-effects. 
The chemical modifications allow for these drugs to have 
high stability, but they are still susceptible to lysosomal 
degradation, which allows them to be cleared from the body 
after administration [6].  
Phosphorothioate Modified ASOs and the Extra-cellular 
Matrix 
The extra-cellular matrix is an area that could hold the key 
for understanding the mechanism for PS-ASO binding and 
cellular internalization. Prevoius work has looked at the role 
of proteins such as fibroblast growth factor receptors 
(FGFR), as a poteintal mechanism of binding for PS-ASOs 
based on the polyanionic charge of other molecules (heparin 
sulfate and suramin ligands) that bind to these receptors [13, 
46]. It was also of interest based on the high expression of the 
FGFRs in the liver, which is a major site of accumulation, 
activation, and degradation of ASO molecules [6]. Previous 
work that has looked at these proteins as well as many other 
heparin binding proteins, such as lamelin and fibronectin 
have been identified has poteintal targets for ASO binding 
based on the role of ASOs binding to the ECM, as well as 
their role in NF-kappaB nuclear transcription regulatory 
factor, as a site specific cellular adhesion blocker [47]. 
Although this reasoning has shown binding of the ASOs to 
the proteins, such as FGFR1 as a target for onset obesity by 
allele specific single nucleotide polymorphisms [48, 49], a clear 
mechanism of internalization from these proteins has 
remained elusive. Currently, there are two potential 
mechanisms that have begun to explain the internalization of 
these molecules; scavenger receptor A, and the stabilin 
receptors [5, 6]. Although these two protein receptors are good 
candidates to help address the question of internalization of 
ASOs, there are still many proteins in the ECM that could 
play a significant role in how these drugs are not only 
binding to cells, but being internalized as well.  
Scavenger Receptor A 
Scavenger receptors are a group of LDL recognition and 
internalization receptors. Roughly two decades ago, 
Bijsterbosch and coworkers detailed how a subset of 
scavenger receptor proteins were implicated in 
internalization of PS-ASOs into the endothelial cells of the 
liver. During the time of this publication there had been three 
types of receptor proteins to be analyzed; class A and B in 
mammalian systems, and class C which came from 
Drosophila [5]. Scavenger receptor A (SR-A) are trimer 
proteins that bind and internalize LDL, preferentially 
modified by acetylation (in-vitro) or by oxidization (in-vivo) 
[50]. The class A receptors (SR-A), specifically types AI and 
AII were well-known which allowed for a comprehensive 
investigation for these targets. Their work led to the 
conclusion that class A receptors were the primary 
internalization mechanism for PS-ASO uptake in the 
endothelial cells of the liver [5]. Further in-vitro and in-vivo 
studies were performed utilizing SR-A receptors for 
internalization, using co-administration of polyanionic 
compounds such as dextran sulfate [51]. These compounds 
were shown to be competitor polyanionic compounds that 
decreased PS-ASO saturation in tissue [51]. Following that 
claim, another group at Ionis Pharaceuticals published work 
that disputed the claim that SR-As were the primary 
scavenger receptors for PS-ASO internalization [52]. That 
work investigated the same PS-ASO sequence as previously 
reported by use of a SR-A murine knockout which 
demonstrated no discernable difference of PS-ASO 
internalization between the WT and SR-A KO mice leading 
them to speculate that SR-A has no substantial effect on the 
pharmacoactivity rates of the PS-ASO [52]. There was 
approximately a 50% decrease of high-affinity uptake 
mechanisms between the WT and KO cell lines, however, 
the authors speculated that other high affinity mechanisms 
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could be responsible for at least 50% of the remaining 
amount internalized. Currently, no new information 
regarding SR-A as a systemic clearance receptor for ASOs is 
available.   
Stabilin-1 and Stabilin-2 
Given the understanding of negatively charged PS-ASO 
interactions with heparin binding domains, it was of interest 
to determine if the class H scavenger receptors, Stabilin-1 
and -2, played a role in PS-ASO systemic clearance and 
internalization. Both receptors bind to similar ligands such as 
heparin [53], advanced glycation end-products [54], and low 
density lipoproteins [55]. These proteins represent a good 
model based on their inability to have a strong binding 
affinity for phosphodiester-containing nucleic acids [56]. 
Stabilin receptors are type I receptors that contain seven 
Fas-1 domains, 20 epidermal growth factor (EGF) domains 
found in 4 clusters, an X-link domain, and a single 
transmembrane domain. Stabilin-1 and Stabilin-2 receptors 
are expressed in many tissues, particularly in key areas of 
PS-ASO accumulation in the body such as the liver, kidney, 
spleen adrenal cortex, macrophages, and lymph nodes [57, 58]. 
One key difference between both Stabilin receptors is that 
Stabilin-2 is expressed as two isoforms; the full-length 
315-HARE and the 190-HARE which is derived from the 
315-HARE by proteolytic cleavage and retains full protein 
functionality [59]. Another important distinction is that both 
receptors have distinct ligands (hyaluronan and several 
chondroitin sulfates for Stabilin-2 and Lactogen and SPARC 
for Stabilin-1) and different affinities for shared ligands 
(heparin, modified LDLs, etc).   
Recent work has indicated that these receptors are 
mechanistically significant in PS-ASO cellular endocytosis 
and clearance [6]. This work has shown that by incorporation 
of 2’-O-MOE modifications with a PS backbone, ASOs are 
internalized at a much higher rate in recombinant cells 
over-expressing either Stabilin-1 or each of the Stabilin-2 
isoforms than in the parental cell line which does not express 
either receptor. The content of PS-ASO in liver and spleen of 
Stabilin-2 knock-out mice is much lower than in the WT 
controls 3 days post-injection [6]. Using competition assays, 
similar chemically modified ASOs are internalized by these 
receptors, however, the 2’MOE second generation ASO has 
the highest rate of internalization by Stabilin receptors. 
PS-ASOs are able to bind to the 190-HARE by ionic 
interaction, allowing for internalization into the cell [6]. Once 
internalized via clathrin mediated endocytosis, the ASOs are 
transported via the endosomal pathway for degradation in the 
lysosome [6]. The increased rate of PS-ASO internalization in 
cell culture experiments also correlated to increased 
knock-down activity of the target gene of interest suggesting 
that once internalized, the ASO is escaping the endosomal 
pathway, leading to increased genetic silencing. Although 
recent work demonstrates how Stabilin receptors are 
implicated in the internalization of PS-ASO, a detailed 
understanding of the mechanism for ASO escape from 
endosomes for RNase H mediated mRNA degradation is 
lacking.  
Conclusion 
Recent and continued work of chemical modifications has 
allowed for progress of ASO drugs for suppressing gene 
expression for therapeutic purposes. Currently, over 35 of 
these drugs are either in clinical trials, or have been approved 
by the FDA for use against a variety of diseases. Although 
much work has been done to increase the selectivity and 
potency of these drugs, while decreasing side effects and 
toxicity, some of the basic mechanisms for PS-ASO 
internalization and activity against their specific targets is 
just beginning to be understood. More mechanisitic work in 
the basic science is required to determine the trafficking and 
activation of productive ASOs in primary cells. Despite these 
obstacles, the field of antisense oligonucleotide therapy has 
proven to be a promising one for current and future treatment 
of genetic disorders.  
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